{
  "name": "VEGA",
  "url": "https://github.com/pauloluniyi/VGEA",
  "citation_info": {
    "source": "pubmed",
    "publication": {
      "pmid": "36738762",
      "doi": "10.1016/s2468-1253(22)00427-7",
      "title": "Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.",
      "authors": [
        "Feagan BG",
        "Sands BE",
        "Sandborn WJ",
        "Germinaro M",
        "Vetter M",
        "Shao J",
        "Sheng S",
        "Johanns J",
        "Pan\u00e9s J",
        "VEGA Study Group"
      ],
      "journal": "The lancet. Gastroenterology & hepatology",
      "publication_date": "2023 Apr",
      "year": "2023",
      "volume": "8",
      "issue": "4",
      "pages": "307-320",
      "pub_types": [],
      "is_software": false,
      "is_tool": false,
      "citation_count": 0
    },
    "formatted_citations": {
      "apa": "BG, F., BE, S., WJ, S., M, G., M, V., J, S., ... Group, V.S. (2023). Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. The lancet. Gastroenterology & hepatology, 8(4), 307-320. https://doi.org/10.1016/S2468-1253(22)00427-7",
      "bibtex": "@article{bg2023,\n  title = {Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial},\n  author = {BG, Feagan and BE, Sands and WJ, Sandborn and M, Germinaro and M, Vetter and J, Shao and S, Sheng and J, Johanns and J, Pan\u00e9s and Group, VEGA Study},\n  year = {2023},\n  journal = {The lancet. Gastroenterology & hepatology},\n  volume = {8},\n  number = {4},\n  pages = {307-320},\n  doi = {10.1016/S2468-1253(22)00427-7},\n  pmid = {36738762},\n}",
      "mla": "BG, Feagan, et al. \"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.\" The lancet. Gastroenterology & hepatology, vol. 8, no. 4, 2023, pp. 307-320. DOI: 10.1016/S2468-1253(22)00427-7"
    }
  },
  "last_updated": "2025-08-05T04:46:39.934111"
}